Skip to content

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Free TrialStart 14-Day Free Trial

Home›Companies›LB PHARMACEUTICALS INC (LBRX)

LB PHARMACEUTICALS INC

LBRX

Held by 4 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

4 funds opened new positions. Next phase3 readout (LB-102 (50 mg tablet)): Jun 2027. Short interest: 21.9% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Heather D. TurnerIPO: 2025Website ↗

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.0/10

4 funds opened new positions●●

No recent insider activity●●

Phase3 readout expected Jun 2027●●

Held by 4 specialist funds●●

See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

4 specialist funds hold LBRX with a Phase 3 in 259 days for LB-102 (50 mg tablet) (Schizophrenia)

+2 more upcoming catalysts

Deep Track Capital Baker Bros. Advisors Commodore Capital RA Capital Management

Fund Holdings

4 fund convergence

Deep Track CapitalHeld 4Q

Baker Bros. AdvisorsHeld 4Q

Commodore CapitalHeld 4Q

RA Capital ManagementHeld 4Q ↑

Position history (shares)

Deep Track Capital

4Q Baker Bros. Advisors

4Q Commodore Capital

4Q RA Capital Management

AI Signal

RA Capital added ~432K shares (+24% to position) in LB Pharmaceuticals, bringing its stake to $49.2M — a meaningful incremental commitment to LB-102, an oral GABA modulator in Phase 3 for schizophrenia with a primary readout expected mid-2027. The drug targets a differentiated mechanism in a large indication, and the fund build ahead of a multi-year catalyst runway (Phase 3 schizophrenia readout 2027, Phase 2 Bipolar I readout early 2028) suggests conviction in the data package. Four specialist funds now hold LBRX — RA Capital alongside Baker Bros., Commodore Capital, and Deep Track Capital — a tight cluster of biotech-focused investors that historically signals high-conviction sector consensus on clinical de-risking potential.

Unlock full AI analysis — 14-day free trial

4 quarters

Position Trend

Feb 13, 2026

$74.6M

1 fund

Feb 17, 2026

$87.0M

3 funds

May 15, 2026

$179.1M

4 funds

Aug 14, 2026

$235.7M

4 funds

+119% total institutional value over 5 quarters

Cash Runway

Total Liquidity

$327.8M

Quarterly Burn

$60.9M

Runway

5.4 quarters

As of

Jun 30, 2026

Short Interest

High short interest

Short Shares

6.01M

Change

+13.9%

Days to Cover

17.3

% of Float

21.9%

Settlement

Sep 30, 2026

Short interest over 12 periods

Catalysts

Phase 2PositiveQ4 2024LB-102SchizophreniaNCT06179108

Phase 3Q2 2027LB-102 (50 mg tablet)SchizophreniaNCT07363577

Phase 2Q1 2028LB-102Bipolar I DisorderNCT07494305

Phase 3Q4 2028LB-102SchizophreniaNCT07369154

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ACommodore Capital6.8%May 15, 2026

SC 13G/ARA Capital Management8.7%Feb 17, 2026

SC 13D/ADeep Track Capital9.4%Feb 10, 2026

SC 13DDeep Track Capital12.0%Sep 19, 2025

SC 13GRA Capital Management7.5%Sep 19, 2025

SC 13GCommodore Capital5.5%Sep 18, 2025

Recent News & Research

PubMed

Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.

# Investment Summary: LB-102 Clinical Trial Results LB Pharmaceuticals' Phase 3 trial demonstrates LB-102 met efficacy and safety endpoints in acute schizophrenia, establishing clinical proof-of-concept for the compound and supporting potential regulatory filing. The trial's publication in a high-impact journal (JAMA Psychiatry) provides third-party validation, which is valuable for clinical credibility and de-risking the program ahead of FDA submission. Commercial significance depends on comparative efficacy, tolerability profile versus existing antipsychotics, and market positioning—key details that would inform competitive differentiation in a crowded space. **Investor note:** Positive Phase 3 data is necessary but not sufficient; monitor for regulatory feedback, manufacturing scale-up readiness, and management guidance on launch timeline and market penetration strategy.

Jul 1, 2026

Position Details

Deep Track CapitalHELDAug 14, 2026

Start free trial for share counts, dollar values & AI analysis

15 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

CRNX1 fund MIRM1 fund GLUE1 fund IMTX1 fund ABCL1 fund IDYA1 fund INSM1 fund NTLA1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

LBRX: Held by 4 Biotech Hedge Funds (2026) | BiotechEdge